Table 3.
Neuroactive steroid concentrations (ng/ml) before and after estrogen or placebo treatment in depressed menopausal women on SSRIs and healthy menopausal controls
| Depressed | Control | ||||
|---|---|---|---|---|---|
| Baseline | End of treatment | Baseline | End of treatment | ||
| PROG | Placebo | 1.07 ± 0.37 | 1.06 ± 0.13 | 1.03 ± 0.16 | 1.07 ± 0.26 |
| Estrogen | 1.07 ± 0.14 | 1.01 ± 0.23 | 0.89 ± 0.23 | 0.98 ± 0.26 | |
| ALLO | Placebo | 4.18 ± 1.17 | 3.99 ± 0.44 | 7.39 ± 2.84 | 6.10 ± 1.66 |
| Estrogen | 4.51 ± 1.16 | 4.30 ± 0 .96 | 4.62 ± 0.54 | 8.38 ± 6.98 | |
| THDOC | Placebo | 1.64 ± 1.00 | 1.84 ± 0.90 | 8.19 ± 8.58 | 8.98 ± 10.11 |
| Estrogen | 1.75 ± 0.79 | 2.00 ± 0.96 | 1.28 ± 1.12 | 1.23 ± 1.01 | |
| DHEA | Placebo | 1.03 ± 0.49 | 0.87 ± 0.58 | 1.32 ± 0.90 | 1.19 ± 0.48 |
| Estrogen | 0.59 ± 0.41 | 0.88 ± 0.80 | 1.81 ± 1.29 | 1.93 ± 1.04 | |
No significant changes in NAS after estrogen or placebo treatment in depressed or healthy menopausal women